Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 7:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 243 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Escitalopram Oxalate Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Aripiprazole and Lexapro Drug Interaction Study

NCT00361790
View directory record Official record
Conditions
Healthy
Interventions
Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2013 · Synced Oct 12, 2026, 7:54 AM EDT
Completed Phase 4 Interventional

Escitalopram for the Treatment of Self-Injurious Skin Picking

NCT00115011
View directory record Official record
Conditions
Impulse Control Disorders
Interventions
Escitalopram
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2008 · Synced Oct 12, 2026, 7:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Selective Serotonin Reuptake Inhibitors (SSRIs) and an Opioid on Ventilation

NCT05470465
View directory record Official record
Conditions
Hypercapnia, Ventilatory Depression
Interventions
Placebo and Oxycodone, Paroxetine and Oxycodone, Escitalopram and Oxycodone
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 12, 2026, 7:54 AM EDT
Completed Phase 4 Interventional Results available

The Effects of Eszopiclone and Lexapro on Prefrontal Glutamate and GABA in Depression With Anxiety and Insomnia

NCT00826111
View directory record Official record
Conditions
Depression, Anxiety, Insomnia
Interventions
Eszopiclone, Placebo
Drug
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2012 · Synced Oct 12, 2026, 7:54 AM EDT
Completed Phase 2 Interventional Results available

Lexapro for the Treatment of Traumatic Brain Injury (TBI) Depression & Other Psychiatric Conditions

NCT01368432
View directory record Official record
Conditions
TBI, Major Depression, Other Psychiatric Disorders
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 12, 2026, 7:54 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

International Study to Predict Optimised Treatment - in Depression

NCT00693849
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Sertraline, Venlafaxine-XR
Drug
Lead sponsor
BRC Operations Pty. Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,688 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2019
U.S. locations
13
States / cities
Colton, California • Mission Viejo, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 12, 2026, 7:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth

NCT02553161
View directory record Official record
Conditions
Depression, Anxiety, Bipolar Disorder
Interventions
Escitalopram, Cognitive behavioral Psychotherapy
Drug · Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Stanford, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Oct 12, 2026, 7:54 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Dose-finding Study of Selective Serotonin Reuptake Inhibitors to Enhance Neuroplasticity

NCT04221256
View directory record Official record
Conditions
Stroke, Ischemic
Interventions
Administration of SSRI escitalopram, Paired Associative stimulation, Administration of Placebo
Drug · Behavioral
Lead sponsor
Burke Medical Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 12, 2026, 7:54 AM EDT
Completed Phase 4 Interventional Results available

Augmenting Antidepressant Treatment With Interpersonal Psychotherapy for Treating Late-life Depression

NCT00177294
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Interpersonal Psychotherapy, Clinical Monitoring
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Oct 12, 2026, 7:54 AM EDT
Terminated Phase 4 Interventional Results available

Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression

NCT03993457
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Bupropion
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 12, 2026, 7:54 AM EDT
Not listed Not applicable Interventional

DBT and Escitalopram in Borderline Personality Disorder

NCT00255554
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Dialectical Behavioral Therapy, Escitalopram
Behavioral · Drug
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2005 · Synced Oct 12, 2026, 7:54 AM EDT
Completed Phase 4 Interventional Results available

Drug Therapy for Generalized Anxiety Disorder Among the Elderly

NCT00105586
View directory record Official record
Conditions
Anxiety Disorders, Generalized Anxiety Disorder
Interventions
Escitalopram
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 12, 2026, 7:54 AM EDT
Terminated Phase 1 Interventional

A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol

NCT03274817
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Escitalopram Pill, Venlafaxine Pill, Placebo Oral Tablet
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 12, 2026, 7:54 AM EDT
Terminated No phase listed Observational

Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder

NCT01598324
View directory record Official record
Conditions
Treatment-Resistant Depression
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Oct 12, 2026, 7:54 AM EDT
Completed Phase 2 Interventional Results available

Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant

NCT00905424
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
15
States / cities
Newport Beach, California • San Diego, California • Bradenton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 12, 2026, 7:54 AM EDT
Completed Phase 3 Interventional Results available

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

NCT04476030
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
51
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 12, 2026, 7:54 AM EDT
Suspended Phase 3 Interventional

Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer

NCT04973930
View directory record Official record
Conditions
Major Depressive Disorder, Breast Cancer, Venlafaxine
Interventions
Interpersonal Psychotherapy, Venlafaxine HCl ER
Behavioral · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 12, 2026, 7:54 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stress and Inflammation in Late-Life Depression

NCT02389465
View directory record Official record
Conditions
Depression, Inflammation
Interventions
Escitalopram + Celecoxib, Escitalopram + Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years to 80 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 12, 2026, 7:54 AM EDT
Completed Phase 4 Interventional

Predicting Treatment Response in Patients With OCD

NCT03993535
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
selective serotonin reuptake inhibitor
Drug
Lead sponsor
University of Sao Paulo
Other
Eligibility
18 Years to 50 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 12, 2026, 7:54 AM EDT
Completed Phase 3 Interventional

An Eight-week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder

NCT00531622
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
saredutant (SR48968), escitalopram, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 12, 2026, 7:54 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

NCT01111552
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Escitalopram, Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Carson, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Oct 12, 2026, 7:54 AM EDT
Completed Phase 4 Interventional Results available

Connectivity Affecting the Antidepressant REsponse Study

NCT02332291
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Bupropion XL
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 12, 2026, 7:54 AM EDT
Completed Phase 2 Interventional

Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

NCT05536414
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Centanafadine, Escitalopram, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
62
States / cities
Yuma, Arizona • Bryant, Arkansas • Glendale, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 12, 2026, 7:54 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder

NCT01436149
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate ), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
47
States / cities
Birmingham, Alabama • Carson, California • Irvine, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 12, 2026, 7:54 AM EDT